PDF(Pubmed)
Abstract：
UNASSIGNED: Activin A is a key regulator in liver regeneration, but data evaluating its role in humans after hepatic surgery are limited. In this study we explore the predictive role of circulating activin A, its antagonist follistatin-like 3 (FSTL-3), and their ratio for posthepatectomy liver failure (PHLF) and monitor their levels after surgery, to evaluate their role in human liver regeneration.
UNASSIGNED: Activin A and FSTL-3 levels were assessed in 59 patients undergoing liver surgery. Using receiver operating characteristic analysis, we evaluated the predictive potential of activin A, FSTL-3, and their ratio.
UNASSIGNED: While perioperative dynamics of activin A and FSTL3 were significantly affected by hepatic resection (activin A P = .045, FSTL-3 P = .005), their functionally relevant ratio did not significantly change (P = .528). Neither activin A nor FSTL-3 alone but only their ratio exhibited a significant predictive potential for PHLF (area under the curve: 0.789, P = .038). Patients with low preoperative activin A/FSTL-3 ratio were found to more frequently suffer from PHLF (0.017) and morbidity (0.005).
UNASSIGNED: Activin A/FSTL-3 ratio predicts PHLF and morbidity. Its significance in preoperative patient assessment needs to be further validated in larger, independent cohorts.
UNASSIGNED: Activin A and FSTL-3 levels were assessed in 59 patients undergoing liver surgery. Using receiver operating characteristic analysis, we evaluated the predictive potential of activin A, FSTL-3, and their ratio.
UNASSIGNED: While perioperative dynamics of activin A and FSTL3 were significantly affected by hepatic resection (activin A P = .045, FSTL-3 P = .005), their functionally relevant ratio did not significantly change (P = .528). Neither activin A nor FSTL-3 alone but only their ratio exhibited a significant predictive potential for PHLF (area under the curve: 0.789, P = .038). Patients with low preoperative activin A/FSTL-3 ratio were found to more frequently suffer from PHLF (0.017) and morbidity (0.005).
UNASSIGNED: Activin A/FSTL-3 ratio predicts PHLF and morbidity. Its significance in preoperative patient assessment needs to be further validated in larger, independent cohorts.
摘要：
■激活素A是肝脏再生的关键调节剂，但是评估其在肝脏手术后在人类中作用的数据有限。在这项研究中，我们探讨了循环激活素A的预测作用，其拮抗剂卵泡抑素样3（FSTL-3），以及它们在手术后肝功能衰竭（PHLF）中的比例，并在手术后监测它们的水平，评估它们在人类肝脏再生中的作用。
■在59例接受肝脏手术的患者中评估了激活素A和FSTL-3的水平。利用接收机工作特性分析,我们评估了激活素A的预测潜力，FSTL-3及其比率。
■虽然激活素A和FSTL3的围手术期动力学受到肝切除术的显着影响（激活素AP=.045，FSTL-3P=.005），其功能相关比率无显著变化(P=.528).单独的活化素A和FSTL-3均未表现出显著的PHLF预测潜力(曲线下面积:0.789,P=.038)。术前激活素A/FSTL-3比率较低的患者更容易患PHLF（0.017）和发病率（0.005）。
■激活素A/FSTL-3比值可预测PHLF和发病率。其在术前患者评估中的意义有待进一步验证,独立队列。
■在59例接受肝脏手术的患者中评估了激活素A和FSTL-3的水平。利用接收机工作特性分析,我们评估了激活素A的预测潜力，FSTL-3及其比率。
■虽然激活素A和FSTL3的围手术期动力学受到肝切除术的显着影响（激活素AP=.045，FSTL-3P=.005），其功能相关比率无显著变化(P=.528).单独的活化素A和FSTL-3均未表现出显著的PHLF预测潜力(曲线下面积:0.789,P=.038)。术前激活素A/FSTL-3比率较低的患者更容易患PHLF（0.017）和发病率（0.005）。
■激活素A/FSTL-3比值可预测PHLF和发病率。其在术前患者评估中的意义有待进一步验证,独立队列。
